With an impact factor of 35.7, the European Heart Journal, the flagship publication of the European Society of Cardiology, is one of the three most relevant journals in Cardiology world-wide. The selection into this Top 10 list thus signifies the importance of our work:

Our manuscripts showed for the first time that gene therapy can successfully correct the short QT syndrome phenotype on all levels and prevent arrhythmias in an animal model. The short QT syndrome is a rare but potentially lethal genetic rhythm disorder, which can cause sudden cardiac death already in young, apparently healthy individuals. Thus far, no therapy treating the underlying disease cause has been available. Our proof of concept study marks a paradigm shift towards gene therapy approaches to prevent sudden cardiac death.

Congratulations to the whole team and particularly the first author Dr. Saranda Nimani!

Link to press release: Gentherapie korrigiert erstmals lebensbedrohliche Herzrhythmusstörung im Tiermodell - Insel Gruppe AG